• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含腈基弹头的半胱氨酸蛋白酶共价可逆抑制剂:病毒和寄生虫疾病领域的最新进展。

Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.

机构信息

Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.

Department of Biotechnology, Chemistry and Pharmacy, DoE Department of Excellence 2018-2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.

出版信息

Molecules. 2022 Apr 15;27(8):2561. doi: 10.3390/molecules27082561.

DOI:10.3390/molecules27082561
PMID:35458759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9029279/
Abstract

In the field of drug discovery, the nitrile group is well represented among drugs and biologically active compounds. It can form both non-covalent and covalent interactions with diverse biological targets, and it is amenable as an electrophilic warhead for covalent inhibition. The main advantage of the nitrile group as a warhead is mainly due to its milder electrophilic character relative to other more reactive groups (e.g., -CHO), reducing the possibility of unwanted reactions that would hinder the development of safe drugs, coupled to the ease of installation through different synthetic approaches. The covalent inhibition is a well-assessed design approach for serine, threonine, and cysteine protease inhibitors. The mechanism of hydrolysis of these enzymes involves the formation of a covalent acyl intermediate, and this mechanism can be exploited by introducing electrophilic warheads in order to mimic this covalent intermediate. Due to the relevant role played by the cysteine protease in the survival and replication of infective agents, spanning from viruses to protozoan parasites, we will review the most relevant and recent examples of protease inhibitors presenting a nitrile group that have been introduced to form or to facilitate the formation of a covalent bond with the catalytic cysteine active site residue.

摘要

在药物发现领域,腈基在药物和具有生物活性的化合物中广泛存在。它可以与各种生物靶标形成非共价和共价相互作用,并且可以作为共价抑制的亲电弹头。腈基作为弹头的主要优点主要归因于其相对于其他更具反应性的基团(例如 -CHO)的较温和的亲电性,降低了阻碍安全药物开发的不必要反应的可能性,加上通过不同合成方法安装的容易性。共价抑制是丝氨酸、苏氨酸和半胱氨酸蛋白酶抑制剂的一种经过充分评估的设计方法。这些酶的水解机制涉及形成共价酰基中间体,并且可以通过引入亲电弹头来利用这种机制,以模拟这种共价中间体。由于半胱氨酸蛋白酶在感染性剂的存活和复制中发挥着相关作用,从病毒到原生动物寄生虫,我们将综述带有腈基的蛋白酶抑制剂的最新和最相关的实例,这些抑制剂被引入以形成或促进与催化半胱氨酸活性位点残基形成共价键。

相似文献

1
Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.含腈基弹头的半胱氨酸蛋白酶共价可逆抑制剂:病毒和寄生虫疾病领域的最新进展。
Molecules. 2022 Apr 15;27(8):2561. doi: 10.3390/molecules27082561.
2
Identification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of Leishmania mexicana cysteine protease CPB.鉴定半卡巴腙、硫代卡巴腙和三嗪腈类化合物为墨西哥利什曼原虫半胱氨酸蛋白酶 CPB 的抑制剂。
PLoS One. 2013 Oct 16;8(10):e77460. doi: 10.1371/journal.pone.0077460. eCollection 2013.
3
Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?半胱氨酸蛋白酶跨类抑制剂可以实现选择性吗?
J Med Chem. 2019 Dec 12;62(23):10497-10525. doi: 10.1021/acs.jmedchem.9b00683. Epub 2019 Aug 15.
4
A comparative study of warheads for design of cysteine protease inhibitors.用于设计半胱氨酸蛋白酶抑制剂的弹头比较研究。
Bioorg Med Chem Lett. 2017 Nov 15;27(22):5031-5035. doi: 10.1016/j.bmcl.2017.10.002. Epub 2017 Oct 3.
5
Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.二肽基腈对克氏锥虫半胱氨酸蛋白酶抑制的实验研究与计算建模。
Phys Chem Chem Phys. 2018 Sep 26;20(37):24317-24328. doi: 10.1039/c8cp03320j.
6
Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.利用半胱氨酸反应性小分子进行针对锥虫病的药物发现。
Expert Opin Drug Discov. 2012 Apr;7(4):353-66. doi: 10.1517/17460441.2012.668520. Epub 2012 Mar 6.
7
Substitution-Induced Mechanistic Switching in SAr-Warheads for Cysteine Proteases.巯基靶向头(SAr)在半胱氨酸蛋白酶中的取代诱导的机制转换。
Molecules. 2024 Jun 4;29(11):2660. doi: 10.3390/molecules29112660.
8
Crystal structure of Leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor.墨西哥利什曼原虫半胱氨酸蛋白酶 B 与高亲和力的印苦楝肽腈抑制剂复合物的晶体结构。
Bioorg Med Chem. 2020 Nov 15;28(22):115743. doi: 10.1016/j.bmc.2020.115743. Epub 2020 Sep 6.
9
Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.半胱氨酸蛋白酶 Cruzain 的可逆和不可逆共价抑制机制评估。
J Chem Inf Model. 2020 Mar 23;60(3):1666-1677. doi: 10.1021/acs.jcim.9b01138. Epub 2020 Mar 10.
10
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.一种评估多种含腈化合物亲电性和反应活性的通用方法。
Bioorg Med Chem Lett. 2007 Feb 15;17(4):998-1002. doi: 10.1016/j.bmcl.2006.11.044. Epub 2006 Nov 17.

引用本文的文献

1
Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding.二聚体严重急性呼吸综合征冠状病毒3C样蛋白酶(SARS-CoV-2 Mpro)的抑制表现出正协同性以及共价和非共价结合的混合情况。
iScience. 2025 May 28;28(7):112773. doi: 10.1016/j.isci.2025.112773. eCollection 2025 Jul 18.
2
Covalent DNA-Encoded Library Workflow Drives Discovery of SARS-CoV-2 Nonstructural Protein Inhibitors.共价DNA编码文库工作流程推动了SARS-CoV-2非结构蛋白抑制剂的发现。
J Am Chem Soc. 2024 Dec 11;146(49):33983-33996. doi: 10.1021/jacs.4c12992. Epub 2024 Nov 22.
3
Advances in the Search for SARS-CoV-2 M and PL Inhibitors.

本文引用的文献

1
Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital Trypanosoma cruzi Infection.全球化新时代的查加斯病全球控制和管理:先天性克氏锥虫感染的深入观察。
Clin Microbiol Rev. 2022 Apr 20;35(2):e0015221. doi: 10.1128/cmr.00152-21. Epub 2022 Mar 3.
2
Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.在一种新的克氏锥虫病药物发现方法中,对多个克氏锥虫靶标进行检查。
Bioorg Med Chem. 2022 Mar 15;58:116577. doi: 10.1016/j.bmc.2021.116577. Epub 2022 Feb 1.
3
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
新型冠状病毒M和PL抑制剂的研究进展
Pathogens. 2024 Sep 24;13(10):825. doi: 10.3390/pathogens13100825.
4
Advances in Cysteine Protease B Inhibitors for Leishmaniasis Treatment.用于治疗利什曼病的半胱氨酸蛋白酶B抑制剂的研究进展。
Curr Drug Targets. 2025;26(2):88-108. doi: 10.2174/0113894501324437240919064715.
5
Enantioconvergent Cross-Nucleophile Coupling: Copper-Catalyzed Deborylative Cyanation.对映收敛性交叉亲核试剂偶联:铜催化的脱硼基氰化反应
Angew Chem Int Ed Engl. 2024 Dec 2;63(49):e202408745. doi: 10.1002/anie.202408745. Epub 2024 Oct 31.
6
Development and Application of Reversible and Irreversible Covalent Probes for Human and Mouse Cathepsin-K Activity Detection, Revealing Nuclear Activity.用于检测人类和小鼠组织蛋白酶 K 活性的可逆和不可逆的共价探针的开发与应用,揭示核活性。
Adv Sci (Weinh). 2024 Oct;11(38):e2401518. doi: 10.1002/advs.202401518. Epub 2024 Jul 5.
7
Identification of the interaction between MAPK1 and serine protease inhibitor: a preliminary functional study.丝裂原活化蛋白激酶1(MAPK1)与丝氨酸蛋白酶抑制剂相互作用的鉴定:一项初步功能研究。
Acta Biochim Biophys Sin (Shanghai). 2024 Jun 28;56(11):1716-1720. doi: 10.3724/abbs.2024095.
8
Recent Advances on Targeting Proteases for Antiviral Development.靶向蛋白酶用于抗病毒药物研发的最新进展
Viruses. 2024 Feb 27;16(3):366. doi: 10.3390/v16030366.
9
Flavin-Mediated Photocatalysis Provides a General Platform for Sulfide C-H Functionalization.黄素介导的光催化为硫化物C-H官能团化提供了一个通用平台。
ACS Catal. 2024 Jan 31;14(4):2395-2401. doi: 10.1021/acscatal.3c05785. eCollection 2024 Feb 16.
10
Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.通过含有可逆硫代亚胺键加合物的可注射水凝胶实现皮肤的局部和持续巴利昔替尼递药。
Adv Healthc Mater. 2024 May;13(12):e2303256. doi: 10.1002/adhm.202303256. Epub 2024 Jan 26.
SARS-CoV-2 变体的主要蛋白酶突变体仍然对奈玛特韦敏感。
Bioorg Med Chem Lett. 2022 Apr 15;62:128629. doi: 10.1016/j.bmcl.2022.128629. Epub 2022 Feb 16.
4
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.跨膜蛋白酶 TMPRSS2 作为 COVID-19 治疗的治疗靶点。
Int J Mol Sci. 2022 Jan 25;23(3):1351. doi: 10.3390/ijms23031351.
5
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.拟肽腈弹头作为新型冠状病毒3CL蛋白酶抑制剂
RSC Med Chem. 2021 Aug 20;12(10):1722-1730. doi: 10.1039/d1md00247c. eCollection 2021 Oct 20.
6
Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.含腈类药物:作用靶点、作用机制及其构效关系研究
RSC Med Chem. 2021 Aug 10;12(10):1650-1671. doi: 10.1039/d1md00131k. eCollection 2021 Oct 20.
7
Trypanocidal treatment of Chagas disease.恰加斯病的杀锥虫治疗。
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Nov;39(9):458-470. doi: 10.1016/j.eimce.2020.04.012.
8
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
9
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.严重急性呼吸综合征冠状病毒2型主要蛋白酶与蛋白酶抑制剂PF-07321332复合物的晶体结构
Protein Cell. 2022 Sep;13(9):689-693. doi: 10.1007/s13238-021-00883-2. Epub 2021 Oct 22.
10
Recent progress in covalent warheads for in vivo targeting of endogenous proteins.体内靶向内源性蛋白质的共价弹头的最新进展。
Bioorg Med Chem. 2021 Oct 1;47:116386. doi: 10.1016/j.bmc.2021.116386. Epub 2021 Aug 27.